Minoryx Therapeutics, a CataloniaBio & HealthTech member, has received the orphan drug designation in the treatment of Friedreich’s Ataxia from its leading drug candidate, leriglitazone (MIN-102), by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In 2016, the biotech company obtained orphan drug designation granted in addition to X-linked adrenoleukodystrophy (X-ALD).

Minoryx will be able to receive scientific advice in the clinical development and market exclusivity of 7 to 10 years.

Friedreich’s Ataxia (FRDA) is a severe, rare, genetic neurodegenerative disease that affects one in 40,000 people globally and has an onset between 5and 18 years of age. Patients today solely rely on symptomatic treatments to manage their disease.

Leriglitazone has an anti-oxidant, anti-inflammatory and neuroprotective effect. It is currently in late-stage clinical development in FRDA (Phase II) and adrenomyeloneuropathy (Phase II/III).

This week Minoryx participates in the 10th World Orphan Drug Congress held in Barcelona with the collaboration of CataloniaBioHT.

Related news:

• Minoryx Therapeutics extends its activities in Belgium
• Minoryx appoints Didier Le Normand as group CFO and general manager of its Belgian subsidiary

Photo: Marc Martinell, co-founder and CEO of Minoryx - © Minoryx Therapeutics